Tumor-associated edema in brain cancer patients: Pathogenesis and management

Expert Review of Anticancer Therapy

Volumn 13, Issue 11, 2013, Pages 1319-1325

  Roth, Patrick ^a,b   Regli, Luca ^b   Tonder, Michaela ^a,b   Weller, Michael ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

boswellic acids; brain tumor; corticorelin acetate; edema; steroids; VEGF

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ANGIOGENESIS INHIBITOR; ARGATROBAN; BEVACIZUMAB; BOSWELLIC ACID; CEDIRANIB; CELECOXIB; CORTICOTROPIN RELEASING FACTOR; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; LOMUSTINE; PLACEBO; STEROID; TEMOZOLOMIDE;

BRAIN CANCER; BRAIN EDEMA; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INJECTION SITE REACTION; INTRACRANIAL PRESSURE; MANAGED CARE; MENTAL DISEASE; MYOPATHY; NONHUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; PERITUMORAL EDEMA; REVIEW; SKIN DISEASE; TREATMENT OUTCOME;

BRAIN EDEMA; BRAIN NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MANAGEMENT; GLUCOCORTICOIDS; HUMANS;

EID: 84887309465     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2013.852473     Document Type: Review

References (74)

1. Osawa T, Tosaka M, Nagaishi M, Yoshimoto Y. Factors affecting peritumoral brain edema in meningioma: special histological subtypes with prominently extensive edema. J. Neurooncol. 111(1), 49-57 (2013).
2. Wong JM, Panchmatia JR, Ziewacz JE et al. Patterns in neurosurgical adverse events: intracranial neoplasm surgery. Neurosurg. Focus 33(5), E16 (2012).
3. Bebawy JF. Perioperative steroids for peritumoral intracranial edema: a review of mechanisms, efficacy, and side effects. J. Neurosurg. Anesthesiol. 24(3), 173-177 (2012).
4. Unger KR, Lominska CE, Chanyasulkit J et al. Risk factors for posttreatment edema in patients treated with stereotactic radiosurgery for meningiomas. Neurosurgery 70(3), 639-645 (2012).
5. Hirano A, Kawanami T, Llena JF. Electron microscopy of the blood-brain barrier in disease. Microsc. Res. Tech. 27(6), 543-556 (1994).
6. Pietsch T, Valter MM, Wolf HK et al. Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol. 93(2), 109-117 (1997).
7. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219(4587), 983-985, (1983).
8. Strugar JG, Criscuolo GR, Rothbart D, Harrington WN. Vascular endothelial growth/permeability factor expression in human glioma specimens: correlation with vasogenic brain edema and tumor-associated cysts. J. Neurosurg. 83(4), 682-689 (1995).
9. Provias J, Claffey K, delAguila L, Lau N, Feldkamp M, Guha A. Meningiomas: role of vascular endothelial growth factor/ vascular permeability factor in angiogenesis and peritumoral edema. Neurosurgery 40(5), 1016-1026 (1997).
10. Dobrogowska DH, Lossinsky AS, Tarnawski M, Vorbrodt AW. Increased blood-brain barrier permeability and endothelial abnormalities induced by vascular endothelial growth factor. J. Neurocytol. 27(3), 163-173 (1998).
11. Ginat DT, Mangla R, Yeaney G, Schaefer PW, Wang H. Correlation between dynamic contrast-enhanced perfusion MRI relative cerebral blood volume and vascular endothelial growth factor expression in meningiomas. Acad. Radiol. 19(8), 986-990 (2012).
12. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 8(8), 610-622 (2007).
13. Chan AS, Leung SY, Wong MP et al. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am. J. Surg. Pathol. 22(7), 816-826 (1998).
14. Goldman CK, Bharara S, Palmer CA et al. Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression. Neurosurgery 40(6), 1269-1277 (1997).
15. Otsuka S, Tamiya T, Ono Y et al. The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas. J. Neurooncol. 70(3), 349-357 (2004).
16. Nassehi D, Sorensen LP, Dyrbye H et al. Peritumoral brain edema in angiomatous supratentorial meningiomas: an investigation of the vascular endothelial growth factor A pathway. APMIS doi:10.1111/apm.12052 (2013) (Epub ahead of print).
17. Black KL, Hoff JT, McGillicuddy JE, Gebarski SS. Increased leukotriene C4 and vasogenic edema surrounding brain tumors in humans. Ann. Neurol. 19(6), 592-595 (1986).
18. Deininger MH, Weller M, Streffer J, Mittelbronn M, Meyermann R. Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo. Acta Neuropathol. 98(3), 240-244 (1999).
19. Temel SG, Kahveci Z. Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma. J. Mol. Histol. 40(5-6), 369-377 (2009).
20. Badie B, Schartner JM, Hagar AR et al. Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation. Clin. Cancer Res. 9(2), 872-877 (2003).
21. Nathoo N, Barnett GH, Golubic M. The eicosanoid cascade: possible role in gliomas and meningiomas. J. Clin. Pathol. 57(1), 6-13 (2004).
22. Pistolesi S, Boldrini L, Gisfredi S et al. Expression of cyclooxygenase-2 and its correlation with vasogenic brain edema in human intracranial meningiomas. Cancer Invest. 25(7), 555-562 (2007).
23. Mayhan WG. VEGF increases permeability of the blood-brain barrier via a nitric oxide synthase/cGMP-dependent pathway. Am. J. Physiol. 276(5 Pt 1), C1148-C1153 (1999).
24. Broholm H, Rubin I, Kruse A et al. Nitric oxide synthase expression and enzymatic activity in human brain tumors. Clin. Neuropathol. 22(6), 273-281 (2003).
25. Bulnes S, Argandona EG, Bengoetxea H, Leis O, Ortuzar N, Lafuente JV. The role of eNOS in vascular permeability in ENU-induced gliomas. Acta Neurochir. Suppl. 106, 277-282 (2010).
26. Shibata S. Ultrastructure of capillary walls in human brain tumors. Acta Neuropathol. 78(6), 561-571 (1989).
27. Stewart PA, Hayakawa K, Hayakawa E, Farrell CL, Del Maestro RF. A quantitative study of blood-brain barrier permeability ultrastructure in a new rat glioma model. Acta Neuropathol. 67(1-2), 96-102 (1985).
28. Liebner S, Fischmann A, Rascher G et al. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol. 100(3), 323-331 (2000).
29. Papadopoulos MC, Saadoun S, Woodrow CJ et al. Occludin expression in microvessels of neoplastic and non-neoplastic human brain. Neuropathol. Appl. Neurobiol. 27(5), 384-395 (2001).
30. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J. Biol. Chem. 274(33), 23463-23467 (1999).
31. Savaskan NE, Heckel A, Hahnen E et al. Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat. Med. 14(6), 629-632 (2008).
32. Badaut J, Lasbennes F, Magistretti PJ, Regli L. Aquaporins in brain: distribution, physiology, and pathophysiology. J. Cereb. Blood. Flow. Metab. 22(4), 367-378 (2002).
33. Saadoun S, Papadopoulos MC, Davies DC, Bell BA, Krishna S. Increased aquaporin 1 water channel expression in human brain tumours. Br. J. Cancer 87(6), 621-623 (2002).
34. Saadoun S, Papadopoulos MC, Davies DC, Krishna S, Bell BA. Aquaporin-4 expression is increased in oedematous human brain tumours. J. Neurol. Neurosurg. Psychiatry 72(2), 262-265 (2002).
35. Warth A, Simon P, Capper D et al. Expression pattern of the water channel aquaporin-4 in human gliomas is associated with blood-brain barrier disturbance but not with patient survival. J. Neurosci. Res. 85(6), 1336-1346 (2007).
36. Mou K, Chen M, Mao Q et al. AQP-4 in peritumoral edematous tissue is correlated with the degree of glioma and with expression of VEGF and HIF-alpha. J. Neurooncol. 100(3), 375-383 (2010).
37. Lambertz N, Hindy NE, Adler C et al. Expression of aquaporin 5 and the AQP5 polymorphism A(-1364)C in association with peritumoral brain edema in meningioma patients. J. Neurooncol. 112(2), 297-305 (2013).
38. Ingraham FD, Matson DD, Mc LR. Cortisone and ACTH as an adjunct to the surgery of craniopharyngiomas. N. Engl. J. Med. 246(15), 568-571 (1952).
39. Galicich JH, French LA, Melby JC. Use of dexamethasone in treatment of cerebral edema associated with brain tumors. J. Lancet 81, 46-53 (1961).
40. Roth P, Wick W, Weller M. Steroids in neurooncology: actions, indications, side-effects. Curr. Opin. Neurol. 23(6), 597-602 (2010).
41. Ryan R, Booth S, Price S. Corticosteroid-use in primary and secondary brain tumour patients: a review. J. Neurooncol. 106(3), 449-459 (2012).
42. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213(4514), 1394-1397 (1981).
43. Reubi JC, Waser B, Vale W, Rivier J. Expression of CRF1 and CRF2 receptors in human cancers. J. Clin. Endocrinol. Metab. 88(7), 3312-3320 (2003).
44. Tjuvajev J, Uehara H, Desai R et al. Corticotropin-releasing factor decreases vasogenic brain edema. Cancer Res. 56(6), 1352-1360 (1996).
45. Wei ET, Gao GC. Corticotropin-releasing factor: an inhibitor of vascular leakage in rat skeletal muscle and brain cortex after injury. Regul. Pept. 33(2), 93-104 (1991).
46. Moliterno JA, Henry E, Pannullo SC. Corticorelin acetate injections for the treatment of peritumoral brain edema. Expert Opin. Investig. Drugs 18(9), 1413-1419 (2009).
47. Villalona-Calero MA, Eckardt J, Burris H et al. A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema. Ann. Oncol. 9(1), 71-77 (1998).
48. Moroz MA, Huang R, Kochetkov T et al. Comparison of corticotropin- releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas. Clin. Cancer Res. 17(10), 3282-3292 (2011).
49. Gamez I, Ryan RP, Keir ST. Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models. Anticancer Res. 30(12), 5037-5042 (2010).
50. Recht L, Mechtler LL, Wong ET, O'Connor PC, Rodda BE. Steroid-sparing effect of corticorelin acetate in peritumoral cerebral edema is associated with improvement in steroid-induced myopathy. J. Clin. Oncol. 31(9), 1182-1187 (2013).
51. Berkman RA, Merrill MJ, Reinhold WC et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J. Clin. Invest. 91(1), 153-159 (1993).
52. Vredenburgh JJ, Cloughesy T, Samant M et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 15(12), 1329-1334 (2010).
53. Gerstner ER, Duda DG, di Tomaso E et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat. Rev. Clin. Oncol. 6(4), 229-236 (2009).
54. Ellingson BM, Cloughesy TF, Lai A et al. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. J. Neurooncol. 106(1), 111-119 (2012).
55. Kamoun WS, Ley CD, Farrar CT et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J. Clin. Oncol. 27(15), 2542-2552 (2009).
56. Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1), 83-95 (2007).
57. Batchelor TT, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28(17), 2817-2823 (2010).
58. Batchelor T, Mulholland P, Neyns B et al. The efficacy of cediranib as monotherapy and in combination with lomustine compared to lomustine alone in patients with recurrent glioblastoma: a phase III randomized study. Neuro. Oncol. 12 (Suppl. 4), iv69-iv78 (2010).
59. Iwamoto FM, Lamborn KR, Robins HI et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro. Oncol. 12(8), 855-861 (2010).
60. Glaser T, Winter S, Groscurth P et al. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br. J. Cancer 80(5-6), 756-765 (1999).
61. Janssen G, Bode U, Breu H, Dohrn B, Engelbrecht V, Gobel U. Boswellic acids in the palliative therapy of children with progressive or relapsed brain tumors. Klin Padiatr. 212(4), 189-195 (2000).
62. Streffer JR, Bitzer M, Schabet M, Dichgans J, Weller M. Response of radiochemotherapy-associated cerebral edema to a phytotherapeutic agent, H15. Neurology 56(9), 1219-1221 (2001).
63. Kirste S, Treier M, Wehrle SJ et al. Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: a prospective, randomized, placebo-controlled, double-blind pilot trial. Cancer 117(16), 3788-3795 (2011).
64. Pang X, Yi Z, Zhang X et al. Acetyl-11- keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res. 69(14), 5893-5900 (2009).
65. Siemoneit U, Koeberle A, Rossi A et al. Inhibition of microsomal prostaglandin E2 synthase-1 as a molecular basis for the anti-inflammatory actions of boswellic acids from frankincense. Br. J. Pharmacol. 162(1), 147-162 (2011).
66. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL, Xie K. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res. 64(6), 2030-2038 (2004).
67. Portnow J, Suleman S, Grossman SA, Eller S, Carson K. A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas. Neuro. Oncol. 4(1), 22-25 (2002).
68. Khan RB, Krasin MJ, Kasow K, Leung W. Cyclooxygenase-2 inhibition to treat radiation-induced brain necrosis and edema. J. Pediatr. Hematol. Oncol. 26(4), 253-255 (2004).
69. Toung TJ, Tyler B, Brem H, Traystman RJ, Hurn PD, Bhardwaj A. Hypertonic saline ameliorates cerebral edema associated with experimental brain tumor. J. Neurosurg. Anesthesiol. 14(3), 187-193 (2002).
70. Palma L, Bruni G, Fiaschi AI, Mariottini A. Passage of mannitol into the brain around gliomas: a potential cause of rebound phenomenon. A study on 21 patients. J. Neurosurg. Sci. 50(3), 63-66 (2006).
71. Carpentier AF, Ferrari D, Bailon O et al. Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients. Eur. J. Neurol. 19(10), 1337-1342 (2012).
72. Hua Y, Keep RF, Schallert T, Hoff JT, Xi G. A thrombin inhibitor reduces brain edema, glioma mass and neurological deficits in a rat glioma model. Acta Neurochir. Suppl. 86, 503-506 (2003).
73. Thompson EM, Pishko GL, Muldoon LL, Neuwelt EA. Inhibition of SUR1 decreases the vascular permeability of cerebral metastases. Neoplasia 15(5), 535-543 (2013).
74. Jiang YS, Wang FR. Caloric restriction reduces edema and prolongs survival in a mouse glioma model. J. Neurooncol. doi:10.1007/s11060-013-1154 (2013) (Epub ahead of print).